Drug Quantity Management – Per Days
Coronavirus – Oral Medications for Treatment of Coronavirus Disease 2019 (COVID-19)

Table of Contents

Product Identifier(s)

Effective 1/1/23 to 4/11/23: 110198, 109875

Effective 4/12/23: 100625, 100443

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Lagevrio™ (molnupiravir capsules)
- Paxlovid™ (nirmatrelvir tablets; ritonavir tablets [co-packaged])

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of oral medications for the treatment of COVID-19. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Drug Quantity Limits

Product	Strength/Dosage Form/Carton Size	Maximum Quantity per 180 Days
Paxlovid™ (nirmatrelvir tablets; ritonavir tablets [co-packaged])	30 tablet carton (contains five daily-dose blister cards containing four nirmatrelvir 150 mg tablets and two ritonavir 100 mg tablets each)	30 tablets (1 carton of 5 blister cards)
	20 tablet carton (contains five daily-dose blister cards containing two nirmatrelvir 150 mg tablets and two 100 mg tablets each)	20 tablets (1 carton of 5 blister cards)
Lagevrio™ (molnupiravir capsules)	200 mg capsules (bottles of 40 capsules each)	40 capsules

Cigna covers quantities as medically necessary when the following criteria are met:

Paxlovid tablets

1. Approve a one-time override for a second course of treatment (either one 30 tablet carton or one 20 tablet carton) if the individual meets BOTH of the following (A and B):
   - **A)** Individual has a repeat diagnosis of COVID-19; AND
     Note: This is a second diagnosis unrelated to the initial diagnosis of COVID-19 which was treated with Paxlovid.
   - **B)** At least 90 days have elapsed since completion of the initial course of Paxlovid for treatment of COVID-19.

Lagevrio capsules

1. Approve a one-time override for a second course of treatment (40 capsules) if the individual meets BOTH of the following (A and B):
   - **A)** Individual is has a repeat diagnosis of COVID-19; AND
     Note: This is a second diagnosis unrelated to the initial diagnosis of COVID-19 which was treated with Lagevrio.
   - **B)** At least 90 days have elapsed since completion of the initial course of Lagevrio for treatment of COVID-19.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Paxlovid contains nirmatrelvir tablets (a SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] main protease inhibitor) co-packaged with ritonavir tablets (a cytochrome P450 [CYP]3A inhibitor).[2] Paxlovid was issued Emergency Use Authorization for the treatment of **mild to moderate coronavirus disease 2019 (COVID-19) in patients ≥ 12 years of age** weighing ≥ 40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Lagevrio is a nucleoside analogue that inhibits SARS-CoV replication by viral mutatgenesis.[1] It was issued Emergency Use Authorization for the treatment of **mild to moderate COVID-19 in adults** with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19, including hospitalization and death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Lagevrio is not for use in patients < 18 years of age.

For both drugs, limitations of authorized use include the following:[1,2]

- Paxlovid and Lagevrio are not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19. For Lagevrio, benefit of treatment has not been observed when treatment was initiated after hospitalization due to COVID-19.

- Paxlovid and Lagevrio are not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
- Paxlovid and Lagevrio are not authorized for use longer than 5 consecutive days.

Of note, the Centers for Disease Control and Prevention states that available evidence suggests that reinfection with SARS-CoV-2 with the same virus variant as the initial infection or reinfection with a different variant are both possible; early reinfection within 90 days of the initial infection can occur.[3]

Dosing
The recommended dose is as follows:[1,2]

- Paxlovid: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all three tablets taken together twice daily (BID) for 5 days. Nirmatrelvir must be co-administered with ritonavir. Failure to correctly co-administer nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect.
  - Renal impairment: No dose adjustment is required for patients with mild renal impairment. In patients with moderate renal impairment, the recommended dose of Paxlovid is 150 mg nirmatrelvir (one 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) BID for 5 days. Use of Paxlovid is not recommended in patients with severe renal impairment.
- Lagevrio: 800 mg (four 200-mg capsules) taken orally every 12 hours for 5 days.

Treatment with Paxlovid or Lagevrio should be initiated as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2. Should a patient require hospitalization after starting treatment, the patient may complete the full 5-day treatment course per the healthcare provider's discretion.

Availability
Paxlovid is supplied in two different dose-packs (cartons)[2]:

- Carton containing 30 tablets divided in five daily-dose blister cards. Each daily blister card contains four nirmatrelvir 150 mg tablets and two ritonavir 100 mg tablets.
- Carton containing 20 tablets divided in five daily-dose blister cards. Each daily blister card contains two nirmatrelvir 150 mg tablets and two ritonavir 100 mg tablets.

Lagevrio is supplied as 200-mg capsules packaged in a bottle of 40 capsules.[1]

References

1. Lagrevrio™ capsules [Fact Sheet, Emergency Use Authorization]. Whitehouse Station, NJ: Merck; August 2022. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. Accessed on September 6, 2022.
2. Paxlovid™ tablets [Fact Sheet, Emergency Use Authorization]. New York, NY: Pfizer; August 2022. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. Accessed on September 6, 2022.
3. Clinical considerations for care of children and adults with confirmed COVID-19: reinfection. Centers for Disease Control and Prevention Web site. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-reinfection.html. Updated May 27, 2022. Accessed on September 2, 2022.

Revision History

Type of Revision	Summary of Changes	Approval Date
Update	08/17/2022: Policy updated to reflect new brand name of molnupiravir tablets, Lagevrio.	NA
Early Annual Revision	**Paxlovid tablets and Lagevrio capsules:** Override criteria were updated to require at least 90 days to have elapsed since completion of the initial course of treatment for COVID-19. Previously, criteria required at least 120 days to have elapsed.	09/07/2022